2025
Survival of patients with metastatic renal cell carcinoma with or without brain metastases.
Hurwitz M, Considine B, Hasson N, Savion Gaiger N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. Journal Of Clinical Oncology 2025, 43: 476-476. DOI: 10.1200/jco.2025.43.5_suppl.476.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsClear cell RCCRenal cell carcinomaImmune checkpoint inhibitor therapyMetastatic clear cell RCCBrain metastasesOverall survivalCell carcinomaImmune checkpoint inhibitor eraPrevalence of brain metastasesMultivariate Cox proportional hazards modelAssociated with poor survivalMedian overall survivalAssociated with poor prognosisCompare overall survivalImproved overall survivalAdverse prognostic indicatorDevelopment of BMSurvival of patientsKaplan-Meier analysisYale Cancer CenterRetrospective cohort studyCox proportional hazards modelsProportional hazards model
2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2014
Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008
Lott JP, Wititsuwannakul J, Lee JJ, Ariyan S, Narayan D, Kluger HH, Lazova R. Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008. Journal Of The American Academy Of Dermatology 2014, 71: 1077-1082. PMID: 25308882, PMCID: PMC6133655, DOI: 10.1016/j.jaad.2014.08.026.Peer-Reviewed Original ResearchConceptsMalignant melanomaSpitzoid malignant melanomasSpitz neviClinical characteristicsRetrospective cohort studyMultivariate logistic regressionMalignant melanoma diagnosisSelect patientsCohort studyYounger patientsClinical featuresSingle institutionMale genderMelanomaSmall lesionsLogistic regressionNeviSmall sample sizeLesionsMelanoma diagnosisDiagnosisUnmeasured confoundingPatientsDescriptive statisticsAge
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply